Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 11/2008

01.11.2008 | Original Article

Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment

verfasst von: Marta Cremonesi, Mahila Ferrari, Mirco Bartolomei, Franco Orsi, Guido Bonomo, Demetrio Aricò, Andrew Mallia, Concetta De Cicco, Guido Pedroli, Giovanni Paganelli

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Radioembolisation with 90Y-microspheres is a new locoregional treatment of hepatic lesions, usually applied as single cycle. Multi-cycle treatments might be considered as a strategy to improve the risk-benefit balance. With the aim to derive suitable information for patient tailored therapy, available patients’ dosimetric data were reviewed according to the linear–quadratic model and converted into biological effective dose (BED) values. Single vs. multi-cycle approaches were compared through radiobiological perspective.

Materials and methods

Twenty patients with metastatic lesions underwent radioembolisation. The 90Y-administered activity (AA) was established in order to respect a precautionary limit dose (40 Gy) for the non-tumoral liver (NTL). BED was calculated setting α/β = 2.5 Gy (NTL), 10 Gy (tumours); T 1/2,eff = T 1/2,phys = 64.2 h; T 1/2,rep = 2.5 h (NTL), 1.5 h (tumours). The BED to NTL was considered as a constraint for multi-cycle approach. The AA for two cycles and the percent variations of AA, tumour dose, BED were estimated.

Results

In one-cycle, for a prescribed BED to NTL of 64 Gy (NTL dose = 40 Gy), AA was 1.7 (0.9–3.2) GBq, tumour dose was 130 (65–235) Gy, and tumour BED was 170 (75–360) Gy. Considering two cycles, ∼15% increase was found for AA and dose to NTL, with unvaried BED for NTL. Tumour dose increase was 20 (10–35) Gy; tumour BED increase was 10 (3–11) Gy. In different protocols allowing 80 Gy to NTL, the BED sparing estimated was ∼50 Gy (two cycles) and 65 Gy (three cycles).

Conclusions

From a radiobiological perspective, multi-cycle treatments would allow administering higher activities with increased tumour irradiation and preserved radiation effects on NTL. Trials comparing single vs. multiple cycles are suggested.
Literatur
1.
Zurück zum Zitat Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251–78.PubMed Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251–78.PubMed
2.
Zurück zum Zitat Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 2006;17:1425–39.PubMed Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 2006;17:1425–39.PubMed
3.
Zurück zum Zitat Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006;17:1571–93.PubMedCrossRef Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006;17:1571–93.PubMedCrossRef
4.
Zurück zum Zitat Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996;23:947–52.PubMedCrossRef Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996;23:947–52.PubMedCrossRef
5.
Zurück zum Zitat Ferrari M, Cremonesi M, Bartolomei M, De Cicco C, Bonomo G, Orsi F, et al. Different evaluations for safe 90Y-microspheres in Selective Internal Radiation Therapy (SIRT). Eur J Nucl Med Mol Imaging. 2007;34(2 Suppl):S178. Ferrari M, Cremonesi M, Bartolomei M, De Cicco C, Bonomo G, Orsi F, et al. Different evaluations for safe 90Y-microspheres in Selective Internal Radiation Therapy (SIRT). Eur J Nucl Med Mol Imaging. 2007;34(2 Suppl):S178.
6.
Zurück zum Zitat Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 2006;47:1209–11.PubMed Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med 2006;47:1209–11.PubMed
7.
Zurück zum Zitat DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O’Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94(4 Suppl):1332–48.PubMedCrossRef DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O’Donoghue JA, Sgouros G, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94(4 Suppl):1332–48.PubMedCrossRef
8.
Zurück zum Zitat Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging, 2008 Apr 22. doi:10.1007/s00259-008-0778-1. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging, 2008 Apr 22. doi:10.​1007/​s00259-008-0778-1.
9.
10.
Zurück zum Zitat Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47–51.PubMedCrossRef Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47–51.PubMedCrossRef
11.
Zurück zum Zitat SIR-Spheres Yttrium-90 microspheres [package insert]. Lane Cove, Australia: Sirtex Medical. 2004. SIR-Spheres Yttrium-90 microspheres [package insert]. Lane Cove, Australia: Sirtex Medical. 2004.
12.
Zurück zum Zitat Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, et al. High-dose radioimmunotherapy with 90Y-Ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med 2007;48:1871–9.PubMedCrossRef Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, et al. High-dose radioimmunotherapy with 90Y-Ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med 2007;48:1871–9.PubMedCrossRef
14.
Zurück zum Zitat Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–7.PubMed
15.
Zurück zum Zitat Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol 2006;29:562–7.PubMedCrossRef Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol 2006;29:562–7.PubMedCrossRef
16.
Zurück zum Zitat Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–22.PubMed Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–22.PubMed
17.
Zurück zum Zitat Garrean S, Espat NJ. Yttrium-90 internal radiation therapy for hepatic malignancy. Surgical Oncology 2005;14:179–93.PubMedCrossRef Garrean S, Espat NJ. Yttrium-90 internal radiation therapy for hepatic malignancy. Surgical Oncology 2005;14:179–93.PubMedCrossRef
18.
Zurück zum Zitat Gray BN, Burton MA, Kelleher D, Klemp P, Matz L. Tolerance of the liver to the effects of Yttrium-90 radiation. Int J Radiat Oncol Biol Phys 1990;18:619–23.PubMed Gray BN, Burton MA, Kelleher D, Klemp P, Matz L. Tolerance of the liver to the effects of Yttrium-90 radiation. Int J Radiat Oncol Biol Phys 1990;18:619–23.PubMed
19.
Zurück zum Zitat Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology 2008;247:507–15.PubMedCrossRef Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology 2008;247:507–15.PubMedCrossRef
20.
Zurück zum Zitat Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552–63.PubMed Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552–63.PubMed
21.
Zurück zum Zitat Stubbs RS, O’Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006;76:696–703.PubMedCrossRef Stubbs RS, O’Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006;76:696–703.PubMedCrossRef
22.
Zurück zum Zitat Campbell AM, Bailey IH, A Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46:487–98.PubMedCrossRef Campbell AM, Bailey IH, A Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46:487–98.PubMedCrossRef
23.
Zurück zum Zitat Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994–9.PubMed Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994–9.PubMed
24.
Zurück zum Zitat Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792–800.PubMed Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792–800.PubMed
25.
Zurück zum Zitat Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673–81.PubMed Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673–81.PubMed
26.
Zurück zum Zitat Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16:1641–51.PubMed Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16:1641–51.PubMed
27.
Zurück zum Zitat Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000;45:1023–33.PubMedCrossRef Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000;45:1023–33.PubMedCrossRef
28.
Zurück zum Zitat Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583–92.PubMed Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583–92.PubMed
29.
Zurück zum Zitat Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711–20.PubMedCrossRef Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711–20.PubMedCrossRef
30.
Zurück zum Zitat Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985;11:1699–707.PubMed Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 1985;11:1699–707.PubMed
31.
Zurück zum Zitat Strigari L, D’Andrea M, Maini CL, Sciuto R, Benassi M. Biological optimization of heterogeneous dose distributions in systemic radiotherapy. Med Phys 2006;33:1857–66.PubMedCrossRef Strigari L, D’Andrea M, Maini CL, Sciuto R, Benassi M. Biological optimization of heterogeneous dose distributions in systemic radiotherapy. Med Phys 2006;33:1857–66.PubMedCrossRef
32.
Zurück zum Zitat Bernhardt P, Ahlman H, Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys 2004;31:2628–35.PubMedCrossRef Bernhardt P, Ahlman H, Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys 2004;31:2628–35.PubMedCrossRef
33.
Zurück zum Zitat Atthey M, Nahum AE, Flower MA, McCready VR. Effects of cellular repair and proliferation on targeted radionuclide therapy: a modelling study. Phys Med Biol 2000;45:N15–20.PubMedCrossRef Atthey M, Nahum AE, Flower MA, McCready VR. Effects of cellular repair and proliferation on targeted radionuclide therapy: a modelling study. Phys Med Biol 2000;45:N15–20.PubMedCrossRef
34.
Zurück zum Zitat Antipas V, Dale RG, Coles IP. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol 2001;46(10):2557–69.PubMedCrossRef Antipas V, Dale RG, Coles IP. A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol 2001;46(10):2557–69.PubMedCrossRef
35.
Zurück zum Zitat Jones B, Dale RG. Mathematical models of tumour and normal tissue response. Acta Oncol 1999;38:883–93.PubMedCrossRef Jones B, Dale RG. Mathematical models of tumour and normal tissue response. Acta Oncol 1999;38:883–93.PubMedCrossRef
Metadaten
Titel
Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment
verfasst von
Marta Cremonesi
Mahila Ferrari
Mirco Bartolomei
Franco Orsi
Guido Bonomo
Demetrio Aricò
Andrew Mallia
Concetta De Cicco
Guido Pedroli
Giovanni Paganelli
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0857-3

Weitere Artikel der Ausgabe 11/2008

European Journal of Nuclear Medicine and Molecular Imaging 11/2008 Zur Ausgabe